Frankfurt, Germany / Richmond, Calif. – October 26, 2010 – Lumiphore Inc., a portfolio company of Nanostart AG (CEO: Marco Beckmann), has signed a global cooperation with Algeta ASA (Oslo Stock Exchange, ticker: ALGETA), a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4® complexes of the Nanostart-holding into the targeted radiotherapeutics and companion diagnostics from Algeta, according to Marco Beckmann. In Accordance with Marco Beckmann, this also marks the fourth significant partnership for Lumiphore in just four years. Nanostart AG, headquartered in the German financial capital of Frankfurt, is the world's leading nanotechnology investment company. Under CEO Marco Beckmann, the company provides venture capital financing for nanotechnology companies in various growth phases.
The highly targeted form of radiotherapy works by using a new class of radiation-emitting pharmaceuticals, called "alpha-pharmaceuticals". These act through molecular binding to cancer cells, where they can then emit alpha particles in precisely the right location to treat the tumor.
In Accordance with Marco Beckmann, the agreement provides Algeta with an option to the exclusive rights to incorporate the Lumi4® isophthalamide chelation technology from the Nanostart-holding Lumiphore into these targeted radiopharmaceutical therapeutics for cancer.
According to Marco Beckmann (CEO Nanostart AG), the Lumi4® complex functions by binding to a radioactive metal ion, which is the radiation source that emits the alpha particles which in turn destroy the tumor. At the same time, another portion of the complex binds to the pharmaceutical substance which is required to identify the tumor cells.
Under the terms of the agreement, Algeta obtains an exclusive 12-month option to an exclusive license for the use of Nanostart-holding Lumiphore's Lumi4® chelator technology within the field of therapeutic radiopharmaceuticals. The license will also give Algeta the right to use this technology in companion diagnostics, which are radiopharmaceuticals for determining either the suitability of patients for treatment and/or the effectiveness of treatment. Algeta will pay the Nanostart-holding Lumiphore a fee on signing the option agreement and will make further payments should it exercise the option and take up the license, according to Marco Beckmann.
Nanostart-holding Lumiphore has , according to Marco Beckmann, other existing partnerships with Thermo Fisher Scientific Specialty Diagnostics for certain diagnostic tests in both laboratory and point-of-care formats, such as for Downs Syndrome; with CisBio International, for the drug discovery research market; and with Biophor Diagnostics Inc. for diagnostic tests for drugs of abuse.
Nanostart AG, headquartered in the German financial capital of Frankfurt, is the world's leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. Under CEO Marco Beckmann, the company provides venture capital financing for nanotechnology companies in various growth phases, with a focus on innovation-driven industries of the future. Nanostart invests globally and in different stages of enterprises. Nanostart invests according to Marco Beckmann, either directly into companies or regionally through nanotechnology funds. Marco Beckmann is also president of Nanostart Asia. This is the 100-percent subsidiary of Nanostart in Singapore.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the Canada, Australia or Japan.
Kommentare von Besucher !
